AES 2022 | Activity-dependent gene therapy: promising for pharmaco-resistant focal epilepsy

Gabriele Lignani, PhD, UCL Queen Square Institute of Neurology, London, UK, outlines the promising role of activity-dependent gene therapy in treating any disorder in which only a subpopulation of neurons is pathologically overactive, such as epilepsy. Patients with refractory epilepsy for whom surgery remains the only option to achieve seizure freedom would benefit from the availability of activity-dependent gene therapy. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.